Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma

2.1 Pembrolizumab (Keytruda, MSD), in combination with lenvatinib (Kisplyx, Eisai), is indicated for 'the first-line treatment of advanced renal cell carcinoma in adults'.

2.2 The dosage schedule is available in the summary of product characteristics for pembrolizumab.

2.3 The price of lenvatinib is £1,437 per 30 4‑mg or 10‑mg capsules (excluding VAT; BNF online accessed July 2022). The price of pembrolizumab is £2,630 per 100 mg per 4‑ml vial (excluding VAT; BNF online accessed July 2022).

The companies have commercial arrangements. These make lenvatinib and pembrolizumab available to the NHS with discounts. The sizes of the discounts are commercial in confidence. It is the companies' responsibility to let relevant NHS organisations know details of the discounts.